Effects of perinatal methylphenidate (MPH) treatment in male and female Sprague-Dawley offspring

Neurotoxicology and Teratology

Volumn 42, Issue , 2014, Pages 9-16

  Panos, John J ^a   Law, C Delbert ^a   Ferguson, Sherry A ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

Behavior; Hormone; Methylphenidate; Pregnancy; Rat; Ritalinic acid

Indexed keywords

CORTICOSTERONE; ESTRADIOL; LIOTHYRONINE; LUTEINIZING HORMONE; METHYLPHENIDATE; TESTOSTERONE; THYROXINE; CENTRAL STIMULANT AGENT;

AMINO ACID BLOOD LEVEL; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BRAIN SIZE; CONTROLLED STUDY; DRUG EFFECT; ESTRADIOL BLOOD LEVEL; FEMALE; FLUID INTAKE; FOOD INTAKE; GESTATION PERIOD; MALE; MORTALITY; NONHUMAN; PERINATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROGENY; RAT; TESTOSTERONE BLOOD LEVEL; ANIMAL; ANIMAL MODEL; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BIRTH WEIGHT; BLOOD; CHEMICALLY INDUCED; COMPLICATION; DRUG EFFECTS; EATING; HUMAN; NEWBORN; PATHOLOGY; PATHOPHYSIOLOGY; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE; SPRAGUE DAWLEY RAT; TOXICITY;

ANIMALS; ANIMALS, NEWBORN; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BEHAVIOR, ANIMAL; BIRTH WEIGHT; BODY WEIGHT; CENTRAL NERVOUS SYSTEM STIMULANTS; EATING; ESTRADIOL; FEMALE; HUMANS; MALE; METHYLPHENIDATE; MODELS, ANIMAL; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84893349447     PISSN: 08920362     EISSN: 18729738     Source Type: Journal    
DOI: 10.1016/j.ntt.2014.01.004     Document Type: Article

References (49)

1. American Psychiatric Association Diagnostic and statistical manual of mental disorders 2013, Washington, DC. 5th ed.
2. Aoyama T., Kotaki H., Iga T. Dose-dependent kinetics of methylphenidate enantiomers after oral administration of racemic methylphenidate to rats. J Pharmacobiodyn 1990, 13:647-652.
3. Beckman D.A., Schneider M., Youreneff M., Tse F.L. Developmental toxicity assessment of d, l-methylphenidate and d-methylphenidate in rats and rabbits. Birth Defects Res B Dev Reprod Toxicol 2008, 83:489-501.
4. Biederman J., Mick E.O., Surman C., Doyle R., Hammerness P., Michel E., et al. Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. BMC Psychiatry 2007, 7:49.
5. Briggs G.G., Freeman R.K., Yaffe S.J. Drugs in pregnancy and lactation 2005, Lippincott Williams and Wilkins, Philadelphia, PA. 7th ed.
6. Crawford C.A., Villafranca S.W., Cyr M.C., Farley C.M., Reichel C.M., Gheorghe S.L., et al. Effects of early methylphenidate exposure on morphine- and sucrose-reinforced behaviors in adult rats: relationship to dopamine D2 receptors. Brain Res 2007, 1139:245-253.
7. Crawford C.A., Baella S.A., Farley C.M., Herbert M.S., Horn L.R., Campbell R.H., et al. Early methylphenidate exposure enhances cocaine self-administration but not cocaine-induced conditioned place preference in young adult rats. Psychopharmacology (Berl) 2011, 213:43-52.
8. Crawford C.A., Der-Ghazarian T., Britt C.E., Varela F.A., Kozanian O.O. Novelty-induced conditioned place preference, sucrose preference, and elevated plus maze behavior in adult rats after repeated exposure to methylphenidate during the preweanling period. Behav Brain Res 2013, 246:29-35.
9. Cyr M.C., Morgan M.M. Early methylphenidate exposure enhances morphine antinociception and tolerance in adult rats. Neuropharmacology 2009, 57:673-677.
10. Dafny N., Yang P.B. The role of age, genotype, sex, and route of acute and chronic administration of methylphenidate: a review of its locomotor effects. Brain Res Bull 2006, 68:393-405.
11. Fedele D.A., Lefler E.K., Hartung C.M., Canu W.H. Sex differences in the manifestation of ADHD in emerging adults. J Atten Disord 2012, 16:109-117.
12. Ferguson S.A., Boctor S.Y. Use of food wafers for multiple daily oral treatments in young rats. J Am Assoc Lab Anim Sci 2009, 48:292-295.
13. Ferguson S.A., Garey J., Smith M.E., Twaddle N.C., Doerge D.R., Paule M.G. Preweaning behaviors, developmental landmarks, and acrylamide and glycidamide levels after pre- and postnatal acrylamide treatment in rats. Neurotoxicol Teratol 2010, 32:373-382.
14. Ferguson S.A., Law C.D., Abshire J.S. Developmental treatment with bisphenol A or ethinyl estradiol causes few alterations on early preweaning measures. Toxicol Sci 2011, 124:149-160.
15. Gerasimov M.R., Franceschi M., Volkow N.D., Gifford A., Gatley S.J., Marsteller D., et al. Comparison between intraperitoneal and oral methylphenidate administration: a microdialysis and locomotor activity study. J Pharmacol Exp Ther 2000, 295:51-57.
16. Golub M., Costa L., Crofton K., Frank D., Fried P., Gladen B., et al. NTP-CERHR Expert Panel Report on the reproductive and developmental toxicity of methylphenidate. Birth Defects Res B Dev Reprod Toxicol 2005, 74:300-381.
17. Gray J.D., Punsoni M., Tabori N.E., Melton J.T., Fanslow V., Ward M.J., et al. Methylphenidate administration to juvenile rats alters brain areas involved in cognition, motivated behaviors, appetite, and stress. J Neurosci 2007, 27:7196-7207.
18. Greeley G.H., Kizer J.S. The effects of chronic methylphenidate treatment on growth and endocrine function in the developing rat. J Pharmacol Exp Ther 1980, 215:545-551.
19. Grotjan H.E., Johnson D.C. Temporal variations in reproductive hormones in the immature male rat. Proc Soc Exp Biol Med 1976, 152:381-384.
20. Gualtieri C.T., Kanoy R., Hawk B., Koriath U., Schroeder S., Youngblood W., et al. Growth hormone and prolactin secretion in adults and hyperactive children: relation to methylphenidate serum levels. Psychoneuroendocrinology 1981, 6:331-339.
21. Gualtieri C.T., Wargin W., Kanoy R., Patrick K., Shen C.D., Youngblood W., et al. Clinical studies of methylphenidate serum levels in children and adults. J Am Acad Child Psychiatry 1982, 21:19-26.
22. Guerriero R.M., Hayes M.M., Dhaliwal S.K., Ren J.Q., Kosofsky B.E. Preadolescent methylphenidate versus cocaine treatment differ in the expression of cocaine-induced locomotor sensitization during adolescence and adulthood. Biol Psychiatry 2006, 60:1171-1180.
23. Heinonen O.P., Slone D., Shapiro S. Birth defects and drugs in pregnancy 1977, Publishing Sciences Group, Littleton, MA.
24. Jahn-Eimermacher A., Lasarzik I., Raber J. Statistical analysis of latency outcomes in behavioral experiments. Behav Brain Res 2011, 221:271-275.
25. Kalbfleisch J.D., Prentice R.L. The statistical analysis of failure time data 2002, Wiley-Interscience, Hoboken, NJ. 2nd ed.
26. Kessler R.C., Adler L., Barkley R., Biederman J., Conners C.K., Demler O., et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006, 163:716-723.
27. Kuczenski R., Segal D.S. Exposure of adolescent rats to oral methylphenidate: preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine. J Neurosci 2002, 22:7264-7271.
28. Littell R.C., Milliken G.A., Stroup W.W., Wolfinger R. SAS system for mixed models 1996, SAS Publishing, Cary, NC.
29. Lloyd S.A., Oltean C., Pass H., Phillips B., Staton K., Robertson C.L., et al. Prenatal exposure to psychostimulants increases impulsivity, compulsivity, and motivation for rewards in adult mice. Physiol Behav 2013, 119C:43-51.
30. Marchei E., Farre M., Pardo R., Garcia-Algar O., Pellegrini M., Pacifici R., et al. Correlation between methylphenidate and ritalinic acid concentrations in oral fluid and plasma. Clin Chem 2010, 56:585-592.
31. McFadyen-Leussis M.P., Lewis S.P., Bond T.L., Carrey N., Brown R.E. Prenatal exposure to methylphenidate hydrochloride decreases anxiety and increases exploration in mice. Pharmacol Biochem Behav 2004, 77:491-500.
32. National Research Council Guide for the care and use of laboratory animals 1996, National Academy Press, Washington DC.
33. Patrick K.S., Ellington K.R., Breese G.R. Distribution of methylphenidate and p-hydroxymethylphenidate in rats. J Pharmacol Exp Ther 1984, 231:61-65.
34. Ramos L., Bakhtiar R., Tse F.L. Liquid-liquid extraction using 96-well plate format in conjunction with liquid chromatography/tandem mass spectrometry for quantitative determination of methylphenidate (Ritalin) in human plasma. Rapid Commun Mass Spectrom 2000, 14:740-745.
35. Reimherr F.W., Williams E.D., Strong R.E., Mestas R., Soni P., Marchant B.K. A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. J Clin Psychiatry 2007, 68:93-101.
36. Robison R.J., Reimherr F.W., Marchant B.K., Faraone S.V., Adler L.A., West S.A. Gender differences in 2 clinical trials of adults with attention-deficit/hyperactivity disorder: a retrospective data analysis. J Clin Psychiatry 2008, 69:213-221.
37. Rostain A.L. Attention-deficit/hyperactivity disorder in adults: evidence-based recommendations for management. Postgrad Med 2008, 120:27-38.
38. Spencer T., Wilens T., Biederman J., Faraone S.V., Ablon J.S., Lapey K. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry 1995, 52:434-443.
39. Strubbe J.H., Woods S.C. The timing of meals. Psychol Rev 2004, 111:128-141.
40. Teo S.K., Stirling D.I., Thomas S.D., Hoberman A.M., Christian M.S., Khetani V.D. The perinatal and postnatal toxicity of d-methylphenidate and d, l-methylphenidate in rats. Reprod Toxicol 2002, 16:353-366.
41. Teo S.K., Stirling D.I., Hoberman A.M., Christian M.S., Thomas S.D., Khetani V.D. d-methylphenidate and d, l-methylphenidate are not developmental toxicants in rats and rabbits. Birth Defects Res B Dev Reprod Toxicol 2003, 68:162-171.
42. Thomsen V., Schatzlein D., Mercuro D. Limits of detection in spectroscopy. Spectroscopy 2003, 18:112-114.
43. Volkow N.D., Insel T.R. What are the long-term effects of methylphenidate treatment?. Biol Psychiatry 2003, 54:1307-1309.
44. Volkow N.D., Swanson J.M. Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am J Psychiatry 2003, 160:1909-1918.
45. Volkow N.D., Ding Y.S., Fowler J.S., Wang G.J., Logan J., Gatley J.S., et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psychiatry 1995, 52:456-463.
46. Wargin W., Patrick K., Kilts C., Gualtieri C.T., Ellington K., Mueller R.A., et al. Pharmacokinetics of methylphenidate in man, rat and monkey. J Pharmacol Exp Ther 1983, 226:382-386.
47. Weiss M.D., Gibbins C., Goodman D.W., Hodgkins P.S., Landgraf J.M., Faraone S.V. Moderators and mediators of symptoms and quality of life outcomes in an open-label study of adults treated for attention-deficit/hyperactivity disorder. J Clin Psychiatry 2010, 71:381-390.
48. Wilens T.E., Morrison N.R., Prince J. An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults. Expert Rev Neurother 2011, 11:1443-1465.
49. Willcutt E.G. The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics 2012, 9:490-499.